Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.
Division of Nephrology, Department of Medicine, Hasheminejad Kidney Center, Iran University of Medical Sciences, Tehran, Iran.
Arch Iran Med. 2022 Sep 1;25(9):600-608. doi: 10.34172/aim.2022.95.
Autosomal dominant polycystic kidney disease (ADPKD), one of the common inherited disorders in humans, is characterized by the development and enlargement of renal cysts, often leading to end-stage renal disease (ESRD). In this study, Iranian ADPKD families were subjected to high-throughput DNA sequencing to find potential causative variants facilitating the way toward risk assessment and targeted therapy.
Our protocol was based on the targeted next generation sequencing (NGS) panel previously developed in our center comprising 12 genes involved in PKD. This panel has been applied to investigate the genetic causes of 32 patients with a clinical suspicion of ADPKD.
We identified a total of 31 variants for 32 individuals, two of which were each detected in two individuals. Twenty-seven out of 31 detected variants were interpreted as pathogenic/likely pathogenic and the remaining 4 of uncertain significance with a molecular diagnostic success rate of 87.5%. Among these variants, 25 pathogenic/likely pathogenic variants were detected in 32 index patients (78.1%), and variants of uncertain significance in four individuals (12.5% in ). The majority of variants was identified in (74.2%). Autosomal recessive PKD was identified in one patient, indicating the similarities between recessive and dominant PKD. In concordance with earlier studies, this biallelic variant, p.Arg3277Cys, leads to rapidly progressive and severe disease with very early-onset ADPKD.
Our findings suggest that targeted gene panel sequencing is expected to be the method of choice to improve diagnostic and prognostic accuracy in PKD patients with heterogeneity in genetic background.
常染色体显性多囊肾病(ADPKD)是人类常见的遗传性疾病之一,其特征是肾囊肿的形成和增大,常导致终末期肾病(ESRD)。在这项研究中,对伊朗的 ADPKD 家系进行了高通量 DNA 测序,以寻找潜在的致病变异,从而为风险评估和靶向治疗铺平道路。
我们的方案基于我们中心之前开发的靶向下一代测序(NGS)Panel,该Panel 包含 12 个与 PKD 相关的基因。该Panel 已应用于调查 32 名临床疑似 ADPKD 患者的遗传病因。
我们总共在 32 个人中发现了 31 个变异,其中两个变异分别在两个人中发现。在 31 个检测到的变异中,有 27 个被解释为致病性/可能致病性,其余 4 个为意义不明,分子诊断成功率为 87.5%。在这些变异中,在 32 名索引患者(78.1%)中检测到 25 个致病性/可能致病性变异,在 4 名个体(12.5%)中检测到意义不明的变异。大多数变异发生在 (74.2%)。在一名患者中发现了常染色体隐性 PKD,表明隐性和显性 PKD 之间存在相似性。与早期研究一致,这种双等位基因 变异,p.Arg3277Cys,导致快速进展和严重的疾病,具有非常早发性的 ADPKD。
我们的研究结果表明,针对基因Panel 的测序有望成为改善遗传背景异质性的 PKD 患者诊断和预后准确性的首选方法。